leisure time -WSS

leisure time

author：explore 2025-09-29 22:36:35 - browse：5

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Industry veterans launch new biotech VC with $310M

hotspot

WSS

Dario to buy mental health app maker Twill in cash and stock deal

Dario to buy mental health app maker Twill in cash and stock deal

Key House Republican on health care plans exit from Congress

Why palliative psychiatry is worth discussing

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

leisure time

leisure time

Cancer drug shortages should be causing more outrage

He's a Nobel laureate. Critics say he was misleading on Covid

BioMarin wins approval for gene therapy to treat hemophilia A

The dental labor crisis is a moment of opportunity

Peter Hotez and the public health issue of online harassment

KalVista pill reduced swelling 'attacks' caused by genetic disease

After affirmative action ruling, medical educators look to 'holistic review'

The Readout: Gilead, Bernie Sanders, and other pharma news

Apple is now the first public company to be valued at $3 trillion

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

leisure time

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Obesity drugs seen as possible treatment for liver disease MASH

Medical mystery: When a cough is not just a cough

focus

hotspot

hotspot

leisure time